Related Experiment Videos

[Elderly heart failure patients and the role of beta-blocker therapy]

C W Middeljans-Tijssen1, R W M M Jansen

  • 1Klinisch geriater, Kenniscentrum Geriatrie, UMC St. Radboud Nijmegen.

Tijdschrift Voor Gerontologie En Geriatrie
|May 18, 2006
PubMed

Insights

Beta-blocker therapy is recommended for chronic heart failure with reduced ejection fraction, especially in patients under 80. While evidence is limited for older adults, these drugs are generally well-tolerated and effective for specific heart failure types.

Area of Science:

  • Geriatric Cardiology
  • Pharmacotherapy
  • Heart Failure Management

Context:

  • Chronic heart failure (CHF) presents unique challenges in elderly populations.
  • Optimizing treatment strategies for older adults with CHF is crucial for improving outcomes.
  • The role of beta-blockers in elderly CHF patients requires careful consideration of evidence and tolerability.

Purpose:

  • To review the efficacy and tolerability of beta-blocker therapy in elderly patients with chronic heart failure.
  • To delineate the current evidence supporting beta-blocker use across different age groups and CHF subtypes.
  • To identify specific beta-blocking agents proven effective in stable CHF with left ventricular systolic dysfunction.

Summary:

  • Beta-blockers are recommended for stable chronic heart failure (CHF) with left ventricular systolic dysfunction.
  • Efficacy is proven up to age 80; evidence is limited but tolerability is good for those 80 and over.
  • No proven benefit for heart failure with preserved systolic function; bisoprolol, carvedilol, nebivolol, and metoprolol CR are recommended agents.

Impact:

  • Provides guidance on beta-blocker use in elderly CHF patients, addressing age-related evidence gaps.
  • Highlights the importance of specific beta-blocker agents for effective CHF management in older adults.
  • Contributes to evidence-based clinical practice for geriatric cardiology and heart failure treatment.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...